CTX120 for Multiple Myeloma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called CTX120 for individuals with multiple myeloma, a type of blood cancer, who haven't responded to previous treatments. The study aims to determine the safety and effectiveness of CTX120. Participants receive the drug through an IV after chemotherapy in a single treatment group. Those who have tried at least two different therapies for their multiple myeloma without success might be suitable for this trial. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot have used any systemic anti-tumor therapy or investigational agent within 14 days before joining the trial.
Is there any evidence suggesting that CTX120 is likely to be safe for humans?
Research shows that CTX120 has been tested in mice for treating multiple myeloma, a type of cancer. These studies produced promising results, with the treatment eliminating tumors and extending the mice's lifespan. While encouraging, these results come from animal studies, not human ones.
Currently, CTX120 is in a Phase 1 clinical trial, the first step in testing the treatment in people. The main goal of this phase is to determine the treatment's safety. Phase 1 trials usually involve a small number of participants and focus on how well people tolerate the treatment. Researchers are still collecting safety information for humans, and detailed safety data for CTX120 in people is not yet available.
In summary, while CTX120 has succeeded in animal studies, researchers are still in the early stages of gathering safety information for humans. Participants in the trial will contribute to understanding how safe CTX120 is for people with multiple myeloma.12345Why do researchers think this study treatment might be promising?
Unlike the standard treatments for multiple myeloma, such as chemotherapy, immunotherapy, or stem cell transplant, CTX120 offers a unique approach by using CAR-T cell therapy. This treatment is distinctive because it involves genetically modifying a patient's T-cells to target and destroy cancer cells more effectively. Administered through an IV infusion after lymphodepleting chemotherapy, CTX120 aims to provide a more targeted attack on myeloma cells, potentially leading to better outcomes and fewer side effects compared to conventional therapies. Researchers are excited about CTX120 because it represents a cutting-edge advancement in cancer treatment, offering hope for more personalized and effective options for patients with multiple myeloma.
What evidence suggests that CTX120 might be an effective treatment for multiple myeloma?
Research shows that CTX120, a type of CAR T-cell therapy, may help treat relapsed or hard-to-treat multiple myeloma. CAR T-cell therapy modifies a patient's immune cells to better locate and attack cancer cells. Similar treatments for diseases like large B-cell lymphoma have shown promising results, with some patients experiencing significant improvement. Early results for CTX120 in multiple myeloma indicate that about 75.8% of patients respond to the treatment, and nearly 39% experience a complete or very strong response. Although curing multiple myeloma remains challenging, these findings suggest that CTX120 could help reduce cancer in patients.26789
Who Is on the Research Team?
Annie Weaver, PhD
Principal Investigator
CRISPR Therapeutics
Are You a Good Fit for This Trial?
This trial is for adults over 18 with multiple myeloma that has come back or hasn't responded to treatment after at least two prior therapies. They must be fairly active and healthy, with good organ function, and willing to use birth control for a year post-treatment. People can't join if they've had certain other treatments like gene therapy, have heart issues or infections like HIV, are pregnant/breastfeeding, or have serious mental health conditions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Lymphodepleting Chemotherapy
Participants receive lymphodepleting chemotherapy prior to CTX120 infusion
Treatment
CTX120 is administered by IV infusion
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term Follow-up
Participants are monitored for objective response rate up to 60 months post-infusion
What Are the Treatments Tested in This Trial?
Interventions
- CTX120
Find a Clinic Near You
Who Is Running the Clinical Trial?
CRISPR Therapeutics AG
Lead Sponsor